A retrospective study from a French emergency department including 525 patients with venous thromboembolic disease (VTE) and atrial fibrillation (AF) found no difference in bleeding risk during therapy with direct oral anticoagulants (DOACs) for these medical conditions [1].
The use of DOACs is an integral part in the management of different indications such as AF and VTE; and, as with any anticoagulation treatment, their use may be associated with the occurrence of haemorrhagic complications. Using information from a database in an emergency department, a retrospective study assessed the incidence of haemorrhage in patients with VTE or AF,
The majority of the 525 included patients were treated with a DOAC (i.e. dabigatran, rivaroxaban, or apixaban) for AF (71.6%), another 149 (28.4%) were treated for VTE. Patients with both VTE and AF were excluded. In total, 95 patients were admitted due to haemorrhage: 27 VTE patients (28.4%) and 68 AF patients (71.6%).
The percentage of haemorrhage was comparable in both indications: 18.4% in the VTE group compared with 18.3% in patients with AF. The AF subgroup was significantly older, had more hypertension, and more strokes (all differences P<0.001) compared with the VTE patients. In addition, they had a higher incidence of myocardial infarction, more associated treatments, and a higher haemorrhagic risk score. Despite these striking differences, a subgroup analysis that compared only those patients with AF with bleedings with VTE patients with bleedings showed that only the age difference persisted (78.6 ± 10.2 years in the group with AF compared with 60.6 ± 21.1 in the VTE group; P<0.001).
The authors concluded that despite the distinct differences between AF and VTE patients with DOACs, those who experience bleedings do not differ except for age. Thus, age should be the main concern with regard to bleeding risk when DOACs are prescribed.
Posted on
Previous Article
« Physical rehabilitation improves health outcomes after pulmonary embolism Next Article
Surgical bleeding risk most important determinant of bleeding outcomes »
« Physical rehabilitation improves health outcomes after pulmonary embolism Next Article
Surgical bleeding risk most important determinant of bleeding outcomes »
Table of Contents: ISTH 2020
Featured articles
Haemophilia and Rare Bleeding Disorders
Novel gene therapy leads to normal FIX activity levels in severe haemophilia B
Haemophilia gene therapy: progress and obstacles
Recombinant factor VIII safe and effective in PUPs A-LONG study
What’s New in Anticoagulation
Finding the sweet spot of anticoagulation in AF patients with ACS
Lower embryopathy risk with DOAC versus VKA during pregnancy
Higher thrombotic risk in NSCLC patient with ALK rearrangement
COVID-19 and Thrombosis
Crosstalk between inflammation and coagulation in severe COVID-19 infections
COVID-19 associated with higher VTE rates relative to influenza
Therapeutic anticoagulation not associated with lower mortality rates in COVID-19 ICU patients
COVID-19 not associated with heightened VTE risk after discharge
What’s New in Venous Thromboembolism
Residual pulmonary obstruction may predict risk of VTE recurrence
Less diagnostic delay in CTEPH diagnosis with novel algorithm
Risk of checkpoint inhibitor-associated thromboembolic events important for cancer prognosis
Pearls of the Posters
Surgical bleeding risk most important determinant of bleeding outcomes
Similar bleeding rates in patients with VTE and AF treated with DOACs
Physical rehabilitation improves health outcomes after pulmonary embolism
Guidelines adherence reduces bleeding risk after surgery and childbirth for VWD patients
Factor V Leiden mutation linked to atrial fibrillation
Increased rates of arterial thromboembolism in cancer patients
Related Articles
September 8, 2020
COVID-19 associated with higher VTE rates relative to influenza
September 8, 2020
Less diagnostic delay in CTEPH diagnosis with novel algorithm
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com